Comparative effects of pharmacotherapy on the maintenance of cognitive function

European Psychiatry

Volumn 16, Issue SUPPL. 1, 2001, Pages 35-41

  Allain, H ^a   Schuck S ^a   Mauduit, N ^a   Djemai, M ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Antipsychotics; Clinical trials; Cognition; Dementia; Memory; Pharmacovigilance

Indexed keywords

AMISULPRIDE; CAFFEINE; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; CLOZAPINE; FLUNITRAZEPAM; HALOPERIDOL; HYPNOTIC SEDATIVE AGENT; LORAZEPAM; NEUROLEPTIC AGENT; NICARDIPINE; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SERTINDOLE; TACRINE; TIAPRIDE; ZIPRASIDONE; ZOLPIDEM;

AGED; AGITATION; ALZHEIMER DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEMENTIA; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; GERONTOPSYCHIATRY; HUMAN; MEMORY; MENTAL DISEASE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0035108965     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0924-9338(00)00528-9     Document Type: Conference Paper

References (76)

1. Cognitive and non-cognitive aspects of dementia syndromes: An overview
2. Pharmacology of Alzheimer's disease
3. Experimental and clinical methods in the development of anti-Alzheimer drugs
4. Emotion, anxiolysis and memory
5. Double-blind study of tiapride versus haloperidol and placebo in agitation and aggressiveness in elderly patients with cognitive impairment
6. Post-marketing surveillance of zopiclone in insomnia
7. General safety profile of zolpidem: Safety in elderly, overdose and rebound effects
8. Comparative study of the effects of zopiclone (7.5 mg), zolpidem, flunitrazepam and a placebo on nocturnal cognitive performance in healthy subjects in relation to pharmacokinetics
9. Psychotropes chez le sujet âgé
10. Effect of two doses of Ginkgo biloba extract (Egb 761) on the dual coding test in elderly subjects
11. Anxiolytics in the treatment of BPSD
12. Essai clinique en gériatrie
13. Why there is a need for pharmacovigilance
14. A prospective study of dementia with Lewy bodies
15. The prevalence and phenomenology of psychotic symptoms in dementia sufferers
16. Residual effects of zolpidem 10 mg and zopiclone 7.5 mg versus flunitrazepam 1 mg and placebo on driving performances and ocular saccades
17. Care of the delirious patient
18. Vascular risks and cognition dementia: Results from a cohort study of the very old
19. Behavioural disturbances of dementia in our current nomenclature system diagnostic classification of neuropsychiatric signs and symptoms in patients with dementia
20. Alprazolam as an alternative to low-dose haloperidol in older, cognitively impaired nursing facility patients
21. Differentiating the effects of centrally acting drugs on arousal and memory: An event-related potential study of scopolamine, lorazepam and diphenydramine
22. Familial dementia caused by polymerisation of mutant neuroserpin
23. Melatonin, its receptor and relationships with biological rhythm disorders
24. Thérapie multiconceptuelle dans la maladie d'Alzheimer
25. The impact of the symptoms of dementia on caregivers
26. Dopamine receptors and schizophrenia: Contribution of molecular genetics and clinical neuropsychology
27. Bilan tolerance-efficacité d'un an d'utilisation de la tacrine dans 100 cas de maladie d'Alzheimer
28. Prevention of dementia in randomized double-blind placebo controlled systolic hypertension in Europe (Syst-Eur) trial
29. Hallucinations and associated factors in Alzheimer's disease
30. Neurochemistry and neurotransmitters
31. Quetiapine. A review of its use in schizophrenia
32. A unifying hypothesis of Alzheimer's disease. I. Ageing sets the stage
33. Cognition and anxiety: The cognitive effects of anti-anxiety medication
34. Alteration of regional cerebral glucose utilisation with delusions in Alzheimer's disease
35. Regional cerebral blood flow and cognitive impairment inpatients with Alzheimer's disease-evaluation of an observer-independant analytic approach
36. Could a high cholesterol diet cause Alzheimer's disease in Western Society (hypothesis)
37. Drugs that induce delirium
38. Comparison of the risperidonr and placebo for psychosis and behavioural disturbances associated with dementia a randomized double-blind trial
39. Frontal behavioural inventory: Diagnostic criteria for frontal lobe dementia
40. Pick's disease fronto-temporal dementia, and Pick complex. Emerging concepts
41. A placebo-controlled, double-blind randomized trial of an extract of Ginkgo-biloba for dementia
42. Etude des correlations entre autoestimation de la mémoire, test de la mémoire de vie quotidienne et carnet de vie
43. Amisulpride versus placebo in the medium term treatment of the negative symptoms of schizophrenia
44. Risperidone in the treatment of elderly patients with psychotic disorders
45. Role of atypical antipsychotics in the treatment of psychosis and agitation associated with dementia
46. The efficacy, safety and tolerability of antipsychotics in the elderly
47. Long-term potentiation - A decade of progress?
48. The neurobiology of suicide risk: A review for the clinician
49. Treatment of agitation in patients with dementia
50. 2+/calmoduline-stimulable adenyl cyclases as molecular coincidence detectors in memory formation
51. Pharmacovigilance et pharmacoépidémiologie: Principes, définition, méthodes et acrualités en neurologie
52. Do antipsychotic medications decrease the risk of suicide in patients with schizophrenia
53. Effects of tiapride on electroencephalograms and cognitive functions in the elderly
54. Effects of 50 mg amisulpride on EEG, psychomotor and cognitive functions in healthy sleep deprived subjects
55. The recognition, assessment and management of dementing disorders: Conclusions from the Canadian consensus conference on dementia
56. Delusions in Alzheimer's disease: A review
57. Behavioural pathology in Alzheimer's disease (Behave-AD) rating scale
58. Towards a science of Alzheimer's disease management: A model based upon current knowledge of retrogenesis
59. Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-ARIEN International Workshop
60. Evaluation of efficacy measures in clinical trials for Alzheimer's disease: Does psychometric test performance predicts clinically relevant outcomes [abstract]
61. Simple reaction time as a measure of global attention in Alzheimer's disease
62. The impact of regular multidisciplinary team interventions on psychotropic prescribing in Swedish nursing homes
63. Pharmacologic management of psychosis in dementia
64. Effets indésirables et médicaments de la maladie d'Alzheimer
65. Neuropsychological psychiatric and cerebral blood flow findings in vascular dementia and Alzheimer's disease
66. A comparison of psychiatric symptoms in vascular dementia and Alzheimer's disease
67. Genetic enhancement of learning and memory in mice
68. Treatment of agitation in dementia
69. Memory for places learned long ago is intact after hippocampal damage
70. Clozapine in drug-induced psychosis in Parkinson's disease
71. Acetylcholine and delirium
72. Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals
73. The overlap between Alzheimer's disease and vascular dementia: The role of white matter changes
74. Assessing behavioural symptoms of dementia of the Alzheimer type: Categorical and quantitative approaches
75. Behavioural disturbances of dementia in DSMIV and ICD-10: Fact or fiction